TI
PRME icon

TrueMark Investments’s Prime Medicine PRME Stock Holding History

TrueMark Investments’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-85,183
Closed -$596K – 221
2024
Q1 		$596K Buy
85,183
+10,153
+14% +$77K 0.55% 49
2023
Q4 		$665K Buy
+75,030
New +$578K 0.66% 48

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

TrueMark Investments's PRME Position: Q2 2024 in Review

TrueMark Investments sold out of Prime Medicine (PRME) in Q2 2024, closing a stake of 85,183 shares — an estimated $596K sold.

TrueMark Investments first reported a position in PRME in Q4 2023 and held it in 2 quarters. The position peaked at $665K in Q4 2023. 122 funds tracked by Wall St. Rank hold PRME as of Q2 2024.

  • TrueMark Investments reported no remaining Prime Medicine position as of Q2 2024 after selling out during the quarter.
  • TrueMark Investments sold 85,183 Prime Medicine shares in Q2 2024, an estimated $596K.
  • TrueMark Investments first reported a position in Prime Medicine in Q4 2023 and held it in 2 quarters.
  • TrueMark Investments's Prime Medicine position peaked at $665K in Q4 2023.
  • 122 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2024.

Based on TrueMark Investments's 13F filing for Q2 2024, filed 29 Jul 2024.